Cabaletta Bio Highlights PC-Free Rese-cel Results and $150M Financing, Setting Stage for 2026 Milestones
First Clinical Data Show Durable PC-Free Responses in Pemphigus Vulgaris
Cabaletta Bio’s first quarter 2026 update centers on promising early results from rese-cel, its engineered CAR T cell therapy, in autoimmune disorders. At the ASGCT 2026 Annual Meeting, the company unveiled 6-to-9-month data showing that even the lowest-dose, preconditioning-free (PC-free) infusion of rese-cel led to compelling drug-free responses in half of the pemphigus vulgaris patients studied. This foundational signal supports potentially transformative approaches for severe autoimmune diseases without prolonged immune suppression.
Commercial-Scale, Low-Cost Manufacturing Secured Through Cellares Partnership
The manufacturing side is also seeing a step-change: Cabaletta has locked in a 10-year supply agreement with automation leader Cellares. The deal is structured to enable rese-cel to be produced at scale for thousands of patients each year while attaining what’s described as one of the industry’s lowest costs per batch for autologous cell therapies. Initial clinical experience with Cellares-manufactured cells matched prior standards for expansion and pharmacodynamic effects, supporting a seamlessly scalable transition.
Pivotal and Expansion Trials Across Autoimmune Disease Pipeline Set for 2026 Flow of Data
The RESET development program is progressing on several fronts. Key ongoing and upcoming milestones include:
- RESET-Myositis: Outpatient pivotal trial enrollment progressing; data from this 17-patient cohort may underpin a Biologics License Application (BLA) for rese-cel in myositis by 2027.
- RESET-SLE: PC-free initial data in lupus patients expected 1H26; extended follow-up and higher dose data in the second half.
- RESET-MG: Favorable safety/efficacy data from 13 evaluable patients presented at the AAN 2026 meeting, with major improvements on disease scores.
- RESET-SSc: Complete Phase 1/2 data to be unveiled at the upcoming June EULAR Congress.
2026 Scientific Presentations Timeline
| Study | Event | Presentation | Date |
|---|---|---|---|
| RESET-SLE | EULAR 2026 | Phase 1/2 preconditioning cohort (Poster) | June 4 |
| RESET-Myositis | EULAR 2026 | Longer-term Phase 1/2 update (Oral) | June 4 |
| RESET-SSc | EULAR 2026 | Complete Phase 1/2 data (Symposium) | June 4 |
| RESET program (multiple cohorts) | EULAR 2026 | Translational/Posters | June 6 |
Strong Financial Position Bolstered by $150 Million Capital Raise
Financially, Cabaletta ended the first quarter with $116.6 million in cash and investments. The company subsequently closed an oversubscribed $150 million direct offering, with participation from life sciences investment stalwarts and Eli Lilly. This combined cash position is anticipated to support operations into mid-2027.
| Key Financial Metrics | Q1 2026 | Q1 2025 |
|---|---|---|
| Research & Development Expenses | $37.35M | $29.02M |
| General & Administrative Expenses | $6.94M | $8.12M |
| Cash & Short-term Investments (end of period) | $116.64M | $133.60M |
| Net Loss | $(43.52M) | $(35.94M) |
Leadership and Advisory Board Grows
Further strengthening its scientific leadership, Cabaletta appointed Dr. Francisco Ramrez-Valle of Eli Lilly to its Scientific Advisory Board, adding depth to immunology and clinical development expertise as the company moves toward pivotal readouts and regulatory submissions.
Key Takeaway: Strategic Progress Positions Cabaletta for Pivotal 2026 Announcements
Cabaletta Bio is capitalizing on foundational clinical data and robust finances to advance its pipeline of potentially curative cell therapies. With scalable manufacturing, pivotal trial data, and major presentations slated for 2026, Cabaletta is poised for critical milestones that could reshape treatment for patients with severe autoimmune diseases. Investors and industry watchers can look forward to several data releases and regulatory updates over the next 12 months, with the RESET-Myositis and RESET-SLE programs at the center of attention.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI